Edgewise Therapeutics (EWTX) Capital Expenditures (2020 - 2026)

Edgewise Therapeutics has disclosed Capital Expenditures across 7 years of filings, most recently posting $41000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $41000.0, down 6.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $253000.0 (up 551.79% YoY), and the FY2025 annual result was $256000.0, up 481.82% from the prior year.
• Capital Expenditures came in at $41000.0 for Q1 2026 at Edgewise Therapeutics, down from $209000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $4.4 million in Q1 2023 to a low of -$160000.0 in Q4 2024.
• The 5-year median for Capital Expenditures is $142000.0 (2022), against an average of $505647.1.
• Across the five-year window, Capital Expenditures soared 1313.59% in 2023 and plunged 199.38% in 2024, its largest moves.
• Edgewise Therapeutics' Capital Expenditures stood at -$70000.0 in 2022, then jumped by 330.0% to $161000.0 in 2023, then slumped by 199.38% to -$160000.0 in 2024, then jumped by 230.62% to $209000.0 in 2025, then tumbled by 80.38% to $41000.0 in 2026.
• The last three Capital Expenditures figures came in at $41000.0 (Q1 2026), $209000.0 (Q4 2025), and -$47000.0 (Q3 2025), per Business Quant data.